Home/Filings/4/0000899243-20-003930

4//SEC Filing

ARCH Venture Partners IX, LLC 4

Accession 0000899243-20-003930

CIK 0001745999other

View on SEC.gov Company Profile

Filed

Feb 10, 7:00 PM ET

Accepted

Feb 11, 9:03 AM ET

Size

32.8 KB

Accession

0000899243-20-003930

Insider Transaction Report

Form 4

Period: 2020-02-10

Beam Therapeutics Inc.BEAM

ARCH Venture Partners IX, LLC

10% Owner

Transactions

Conversion
Common Stock
2020-02-10+4,121,519→ 4,121,519 total(indirect: See footnote)
Conversion
Series A-1 Preferred Stock
2020-02-10−1,338,000→ 0 total(indirect: See footnote)
→ Common Stock (1,338,000 underlying)
Conversion
Series A-1 Preferred Stock
2020-02-10−1,338,000→ 0 total(indirect: See footnote)
→ Common Stock (1,338,000 underlying)
Conversion
Series A-2 Preferred Stock
2020-02-10−2,750,336→ 0 total(indirect: See footnote)
→ Common Stock (2,750,336 underlying)
Conversion
Series A-2 Preferred Stock
2020-02-10−2,750,335→ 0 total(indirect: See footnote)
→ Common Stock (2,750,335 underlying)
Conversion
Series B Preferred Stock
2020-02-10−33,184→ 0 total(indirect: See footnote)
→ Common Stock (33,184 underlying)
Conversion
Common Stock
2020-02-10+4,121,520→ 4,121,520 total(indirect: See footnote)
Conversion
Series B Preferred Stock
2020-02-10−33,184→ 0 total(indirect: See footnote)
→ Common Stock (33,184 underlying)

ARCH Venture Fund IX, L.P.

10% Owner

Transactions

Conversion
Series B Preferred Stock
2020-02-10−33,184→ 0 total(indirect: See footnote)
→ Common Stock (33,184 underlying)
Conversion
Common Stock
2020-02-10+4,121,519→ 4,121,519 total(indirect: See footnote)
Conversion
Series A-1 Preferred Stock
2020-02-10−1,338,000→ 0 total(indirect: See footnote)
→ Common Stock (1,338,000 underlying)
Conversion
Common Stock
2020-02-10+4,121,520→ 4,121,520 total(indirect: See footnote)
Conversion
Series A-1 Preferred Stock
2020-02-10−1,338,000→ 0 total(indirect: See footnote)
→ Common Stock (1,338,000 underlying)
Conversion
Series A-2 Preferred Stock
2020-02-10−2,750,335→ 0 total(indirect: See footnote)
→ Common Stock (2,750,335 underlying)
Conversion
Series A-2 Preferred Stock
2020-02-10−2,750,336→ 0 total(indirect: See footnote)
→ Common Stock (2,750,336 underlying)
Conversion
Series B Preferred Stock
2020-02-10−33,184→ 0 total(indirect: See footnote)
→ Common Stock (33,184 underlying)

ARCH Venture Fund IX Overage, L.P.

10% Owner

Transactions

Conversion
Series A-1 Preferred Stock
2020-02-10−1,338,000→ 0 total(indirect: See footnote)
→ Common Stock (1,338,000 underlying)
Conversion
Common Stock
2020-02-10+4,121,520→ 4,121,520 total(indirect: See footnote)
Conversion
Series A-2 Preferred Stock
2020-02-10−2,750,336→ 0 total(indirect: See footnote)
→ Common Stock (2,750,336 underlying)
Conversion
Series A-2 Preferred Stock
2020-02-10−2,750,335→ 0 total(indirect: See footnote)
→ Common Stock (2,750,335 underlying)
Conversion
Series B Preferred Stock
2020-02-10−33,184→ 0 total(indirect: See footnote)
→ Common Stock (33,184 underlying)
Conversion
Series B Preferred Stock
2020-02-10−33,184→ 0 total(indirect: See footnote)
→ Common Stock (33,184 underlying)
Conversion
Common Stock
2020-02-10+4,121,519→ 4,121,519 total(indirect: See footnote)
Conversion
Series A-1 Preferred Stock
2020-02-10−1,338,000→ 0 total(indirect: See footnote)
→ Common Stock (1,338,000 underlying)

CRANDELL KEITH

10% Owner

Transactions

Conversion
Common Stock
2020-02-10+4,121,519→ 4,121,519 total(indirect: See footnote)
Conversion
Series A-1 Preferred Stock
2020-02-10−1,338,000→ 0 total(indirect: See footnote)
→ Common Stock (1,338,000 underlying)
Conversion
Common Stock
2020-02-10+4,121,520→ 4,121,520 total(indirect: See footnote)
Conversion
Series A-1 Preferred Stock
2020-02-10−1,338,000→ 0 total(indirect: See footnote)
→ Common Stock (1,338,000 underlying)
Conversion
Series A-2 Preferred Stock
2020-02-10−2,750,336→ 0 total(indirect: See footnote)
→ Common Stock (2,750,336 underlying)
Conversion
Series A-2 Preferred Stock
2020-02-10−2,750,335→ 0 total(indirect: See footnote)
→ Common Stock (2,750,335 underlying)
Conversion
Series B Preferred Stock
2020-02-10−33,184→ 0 total(indirect: See footnote)
→ Common Stock (33,184 underlying)
Conversion
Series B Preferred Stock
2020-02-10−33,184→ 0 total(indirect: See footnote)
→ Common Stock (33,184 underlying)

ARCH Venture Partners IX, L.P.

10% Owner

Transactions

Conversion
Series A-2 Preferred Stock
2020-02-10−2,750,336→ 0 total(indirect: See footnote)
→ Common Stock (2,750,336 underlying)
Conversion
Common Stock
2020-02-10+4,121,520→ 4,121,520 total(indirect: See footnote)
Conversion
Series A-1 Preferred Stock
2020-02-10−1,338,000→ 0 total(indirect: See footnote)
→ Common Stock (1,338,000 underlying)
Conversion
Series A-2 Preferred Stock
2020-02-10−2,750,335→ 0 total(indirect: See footnote)
→ Common Stock (2,750,335 underlying)
Conversion
Common Stock
2020-02-10+4,121,519→ 4,121,519 total(indirect: See footnote)
Conversion
Series A-1 Preferred Stock
2020-02-10−1,338,000→ 0 total(indirect: See footnote)
→ Common Stock (1,338,000 underlying)
Conversion
Series B Preferred Stock
2020-02-10−33,184→ 0 total(indirect: See footnote)
→ Common Stock (33,184 underlying)
Conversion
Series B Preferred Stock
2020-02-10−33,184→ 0 total(indirect: See footnote)
→ Common Stock (33,184 underlying)

BYBEE CLINTON

10% Owner

Transactions

Conversion
Series B Preferred Stock
2020-02-10−33,184→ 0 total(indirect: See footnote)
→ Common Stock (33,184 underlying)
Conversion
Series A-1 Preferred Stock
2020-02-10−1,338,000→ 0 total(indirect: See footnote)
→ Common Stock (1,338,000 underlying)
Conversion
Series A-1 Preferred Stock
2020-02-10−1,338,000→ 0 total(indirect: See footnote)
→ Common Stock (1,338,000 underlying)
Conversion
Series A-2 Preferred Stock
2020-02-10−2,750,335→ 0 total(indirect: See footnote)
→ Common Stock (2,750,335 underlying)
Conversion
Common Stock
2020-02-10+4,121,519→ 4,121,519 total(indirect: See footnote)
Conversion
Common Stock
2020-02-10+4,121,520→ 4,121,520 total(indirect: See footnote)
Conversion
Series A-2 Preferred Stock
2020-02-10−2,750,336→ 0 total(indirect: See footnote)
→ Common Stock (2,750,336 underlying)
Conversion
Series B Preferred Stock
2020-02-10−33,184→ 0 total(indirect: See footnote)
→ Common Stock (33,184 underlying)

ARCH Venture Partners IX Overage, L.P.

10% Owner

Transactions

Conversion
Series A-2 Preferred Stock
2020-02-10−2,750,335→ 0 total(indirect: See footnote)
→ Common Stock (2,750,335 underlying)
Conversion
Series B Preferred Stock
2020-02-10−33,184→ 0 total(indirect: See footnote)
→ Common Stock (33,184 underlying)
Conversion
Series A-2 Preferred Stock
2020-02-10−2,750,336→ 0 total(indirect: See footnote)
→ Common Stock (2,750,336 underlying)
Conversion
Series B Preferred Stock
2020-02-10−33,184→ 0 total(indirect: See footnote)
→ Common Stock (33,184 underlying)
Conversion
Series A-1 Preferred Stock
2020-02-10−1,338,000→ 0 total(indirect: See footnote)
→ Common Stock (1,338,000 underlying)
Conversion
Series A-1 Preferred Stock
2020-02-10−1,338,000→ 0 total(indirect: See footnote)
→ Common Stock (1,338,000 underlying)
Conversion
Common Stock
2020-02-10+4,121,520→ 4,121,520 total(indirect: See footnote)
Conversion
Common Stock
2020-02-10+4,121,519→ 4,121,519 total(indirect: See footnote)

Footnotes (3)

[F1]Upon closing of the Issuer's initial public offering, each share of Series A-1 Preferred Stock, Series A-2 Preferred Stock, and Series B Preferred Stock automatically converted into shares of Common Stock without payment or further consideration. There was no expiration date for the Series A-1 Preferred Stock, Series A-2 Preferred Stock, or Series B Preferred Stock.
[F2]These shares are directly held by ARCH Venture Fund IX, L.P. ("ARCH IX"). ARCH Venture Partners IX, L.P. ("GPLP"), as the sole general partner of ARCH IX, may be deemed to beneficially own the shares held by ARCH IX. ARCH Venture Partners IX, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by ARCH IX. As managing directors of GPLLC, each of Keith Crandell and Clinton Bybee (the "ARCH Managing Directors"), may be deemed to beneficially own the shares held by ARCH IX. Each of GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any.
[F3]These shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. GPLLC, as the sole general partner of Overage GPLP, may be deemed to beneficially own the shares held by ARCH Overage. As managing directors of GPLLC, each of the ARCH Managing Directors may be deemed to beneficially own the shares held by ARCH Overage. Each of Overage GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION

Issuer

Beam Therapeutics Inc.

CIK 0001745999

→

Entity typeother

IncorporatedDE

Related Parties

filerCIK 0001723174

Filing Metadata

Form type: 4
Filed: Feb 10, 7:00 PM ET
Accepted: Feb 11, 9:03 AM ET
Size: 32.8 KB

View on SEC.gov